HBP caso clínico
-
Upload
eltom-barbaran-vilcatoma -
Category
Documents
-
view
225 -
download
0
Transcript of HBP caso clínico
-
8/18/2019 HBP caso clínico
1/24
“UNIVERSIDAD NACIONAL DE SANCRISTÓBAL DE HUAMANGA”
FACULTAD DE CIENCIAS BIOLÓGICASESCUELA DE FORMACIÓN PROFESIONAL
DE FARMACIA Y BIOQUÍMICA
SEGUIMIENTO FARMACOTERAPEUTICO ENPACIENTES CON HBP
AREA: FARMACOTERAPIA CF-544
DOCENTE: MG. QF. CASTILLO TORRES NANCY
INTEGRANTES:
ARANGO PALOMINO, MADELEINE E.
BARBARAN VILCATOMA, STEPHANY M. JANAMPA ONCEBAY, EDITH GLORIA SANTIAGO CHAVEZ, DANIEL.
DIA DE PRACTICA: MIERCOLES 2:00 4:00 !"
AYACUCHO- PERÚ
202
RACTICA Nº 8
-
8/18/2019 HBP caso clínico
2/24
SEGUIMIENTO FARMACOTERA EUTICO EN ACIENTES
CON HB
I. Objetivos:
#$%&%'() &( "*$++&+( * S*/%"%*$+1()"(+$*)(!3/$%+ SFT * DADER * *& *6())+&&+ 7 )*6+&/%8 * /
(6+ &%+. I*$%9() &+6 R*6/&$(+6 N*($%+6 * &( M*%(%8 RNM +"+
EFECTOS * *& (6+ &%+. I*$%9() &+6 P)+;&*"(6 R*&(%+(+ + &+6 M*%("*$+6 PRM
+"+ CA#SANTES * &+6 RNM * *& (6+ &%+.
II. Intro!""i#n:
L(
-
8/18/2019 HBP caso clínico
3/24
III. C$so C%&ni"o:
D!"#$%%'( ) *(+!#!,!(+!" ,! #*".
A(+!#!,!(+!" &!$".(*!"
V()8 * (>+6, 1/"(+) * 0 !(?/*$*6(>+ 7 6% +$)+6
-
8/18/2019 HBP caso clínico
4/24
*+&/%8. R*9*)* *@!*$+)(%8 !/)/&*$( * +&+) *)+6( 7 +&+) * *&
!*
-
8/18/2019 HBP caso clínico
5/24
I'. RESU(TA)OS
*.+ OFERTA )E( SER'ICIO
-
8/18/2019 HBP caso clínico
6/24
S). B/*+6 (6 $)(6 &( *(&/(%8 ?/* 6* &*
-
8/18/2019 HBP caso clínico
7/24
H*/*(*OCUPACIÓN: EDAD: => *?." SEO M FPESO: TALLA: IMC:23-HISTORIA DE SALUD233 ANTECEDENTES PATOLOGICOSIMAACVICC
DIABETES T%&. IIENF. RENALOBESIDAD HBP
T$./4."%" 1!(."*&$.5(,*C.%+%"&"!,./!/4$*(."*
OTROSHTA $*,. IIEPOCS4.4"+$##%.(%(+!"+%(*
232 PROBLEMAS DE SALUDSNC AP3
LOCOMOTORS3 DIGESTIVO METABOLICAS
.$+62."()*+6.6/*>+4.*6(*%"%*$
+5.%6%+ ;+))+6(.!*)%( *(!*$%$+.+&+) * (;*'(
.*;%&%("/6/&()K. D+&+)*6()$%/&()*6
0.(&(";)*6.+&+))%%*' * /*&&+
2. D+&+) 7+ ()+) **6$+"(+. N(/6*(6 7+8"%$+6
4. D%())*(65. E6$)*>%"%*$+. S*?/*( ;/(&
. H%!+($)*%(. H%!+!+$(6*"%(K. H%!*)&%*"%(20. H%!*)(&*"%(
2.H%!*)+&*6$*)+&*"%(22. E*"(2. H%!*)!+$(6*"%(
S3CARDIOVASCULAR
PIEL OTROS OTROS
24. P(&!%$(%+*625.$(?/%()%(2. H%!+$*6%8
2. A))%$"%(62. A%(2K.;)(%()%(0. H%!+$*6%8+)$.
.E)/!%+*6/$=*(6
2. P)/)%$+.R/;*1(%8
4. B)++*6!(6"+5. D%6!*!6%(. A%+**"(
. N*/$)+!*%(. P)+$*%/)%(K. L*/+!*%(40. F($%(
4. I"!+$*%(42. A6$*%( @3 FIEBRE@@3 SUDORACIÓN@3 ESCALOFRÍOS
233FUNCIONES VITALESFC: FR: T: PA:23@3HABITOS DE CONSUMOALCOHOLNOT%&.E1!(+* - 1*".,8* . /6"1*".",8*
CIGARRILLOSNOE*$/(& (*$%&&(( (*$%&&(( ,! #*!+%*,8*
CAF NO T%!+E*$/(& 2 $('(( * $('(6(
TENOE*$/(& $('((2 $('(( * 2 $('(6(
233 HABITOS ALIMENTICIOS YO DIETETICOSSAL EN LADIETA
ALIMENTOSCONS#ME
H%!+68%(N+)"+68%(H%!*)68%(
A%%+( +"%(6
C()*6 )+(6P*6(+V*)/)(6
F)/$(6 + +6/"*
P(6$(6H()%(6D/&*6
F)%$/)(623
-
8/18/2019 HBP caso clínico
8/24
23=3 PRUEBAS DE LABORATORIOP$!4* R*6/&$(+ F*3DIAGNOSTICON!/.(%*J EPOC "!1!$*J HTAJ DM IIJ HBPJ23K3 MEDICOS TRATANTES:Q3F3 RESPONSABLE:
E(+$!1%"+* 5*$/*#7+%#*: PROBLEMAS DE SALUD FECHA: 22 DE NOVIEMBRE DEL 202N; 00H.*: 02
P$.4!/* ,! "*, : HTA: !"+*,%. 2I(%#%.: H*#! 0 *?."E &*#%!(+! 5! ,%*(."+%#*,. ,! HTA *#! 0*?."J &*$* . #* !"+6 "%%!(,. ( +$*+*/%!(+.
,! I4!$"*$+6( 00/ 0- 03
P$.4!/* ,! "*, 2:PROSTATA HBPI(%#%.: (. %(,%#*P(%*$* $%** HBP + / )
&**, *6$= 6%*+ $)($(("%+=%+6 * +"!)%"%+
P$.4!/* ,! "*, : NEUMONIAI(%#%.: (. %(,%#*E &*#%!(+! $!9!$! +!(!$ 9!4$!J !&!#+.$*#%'(&$!(+* ,! #..$ 1!$,."*J !"#*.5$8." )",.$*#%'( &*$* #* !"+6 "%!(,. +$*+*,. #.(L!1..*#%(. IV 00/ #2@J #*/4%*(,. *
+!$#!$ ,8* * 18* .$* ) 9(*/!(+! *"+*(,. *,."%" &.$ IRC3
P$.4!/* ,! "*, @: DIAI(%#%.: + %%(P(%*$* $%** DMII !()( /(+ G&%"*!%)%( 2" - 4
P$.4!/* ,! "*, : I(%#%.: EPOC "!1!$*P*#%!(+! &$!"!(+* EPOC SEVERA
O+$* %(5.$/*#%'( $!!1*(+! *!$%*"J %(+!$1!(#%.(!" %$$%#*"J .+$." *(+• P*#%!(+! 5/*,.$ >0 &*!+!" * *?.•
I(5.$/*#%'( 46"%#* * .4+!(!$ ." &$.4!/*" ,! "*, P3S3:• P$!.#&*#%'( ) !&!#+*+%1*" ,! &*#%!(+! $!"&!#+. * P3S3J• &!$#!%'( ".4$! ! #.(+$. ,! P3S3 "8(+./*"J "%(."J &*$6/!+$." #*(+%
!1.#%'( ,! * !(5!$/!,*,J %(+!$&$!+*#%'( ,! ." &*$6/!+$." #*(+%9#*
-
8/18/2019 HBP caso clínico
9/24
,.+ ESTA)O )E SITUACION
-.+ FASE )E ESTU)IO
-.*. $to%o&$s
PATOLOGIA
DEFINICION
HIPERPLASIA
BENIGNAPROSTATICA HBP
L( HBP +6%6$*, !+) / &(+, * *& (/"*$+ *& $("(>+ * &( !)+;6$)/%8 !)+)*6%( *& /+ /)%()%+ +"!+*$* *6$=$%+ 7 !+) +$)*& "6/&+ *$)/6+) +"!+*$* %="%+. S/ !)*(&*%( (/"*$()%$*)%+6
-
8/18/2019 HBP caso clínico
10/24
(+)"(& 7 &( $+6 )8%(. A "*%( ?/* &( *1*)"*( *"!*+)(, !/**+$%%((6 +"+ 6/;%) /+6 /($+6 *6(&+*6 + &&*() /( "(&*$(.
DM +%&. 2
L( %(;*$*6 $%!+ 2 *6 /( *1*)"*( ?/* /)( $+( &( %( )8%(('() &/+6( * &( 6()*. C+ 1)*/*%(, &(6 !*)6+(6 + %(;*
(&/+ (& !)%%!%+ 7 *6 !+6%;&* ?/* + $*( 6$+"(6 /)($* "/8, &( !%*& /1)*/*$*6 + 6(( &*$("*$*, 1($%(, + *6 "*%(+ !+) +6 *@!)*+"%%+ *$*)+$8@%+ &( !)%"*)( 7 %#( *' &*6%+(( &( !()* %$*6$%(&, &( "/+6( 6* "/*6$)(
-
8/18/2019 HBP caso clínico
11/24
+ (&(";)*6, "(& (&%*$+, S/6*!$%;%&%( ( +,
-
8/18/2019 HBP caso clínico
12/24
T*)('+6%( $%**(*"=6 / *1*$+
-
8/18/2019 HBP caso clínico
13/24
-.-. RAMs
FRMACO RAMSIRBESARTAN H%!*)!+$(6*"%( K, "()*+ 0, #RI K,
H%!+$*6%8 +)$+6$=$%( 5, 1($%( 4, %())*( ,
%6!*!6%( 2.ALBUTEROL T*";&+) 20, *)%+6%6"+ * 2- (>+6 &+6 %>+6 5,
=/6*(6 0, 1%*;)* ,-K, ;)++*6!(6"+ ,8"%$+6 , +&+) * (;*'( 4-, "()*+ -, $+65, )*(%+*6 (&3)%(6 4, +$%$%6 "*%( ,,*!%6$(@%6 * %>+6 , (/"*$+ *& (!*$%$+ , #TI, ;+( 6*( , *)/$+6 + ($/&*%( ,(/"*$+ * &( 6/+)(%8 , *6(&+1)+6 2,%6!*!6%( -2,
-
8/18/2019 HBP caso clínico
14/24
)*6!%)($+)%+ 6/!*)%+), +&+) (;+"%(&, )*/)%$(%8=%(, *6$)*>%"%*$+, %())*(, 8"%$+6, ($/&*%(,=/6*(, *)/!%8, (&$*)(%8 *& /6$+, F)*/*%( N+D*9%+: 1)($/)( * %"%*$+ , "()*+6 , %6!*!6%( 2, 8"%$+62, )(6< 2, !)/)%$+ , +&+) * *& !*
-
8/18/2019 HBP caso clínico
15/24
=*) * "("( "(6/&%+, **"( &+(&%'(+INSULINANPH
H%!+&/*"%(, )*6%6$*%( ( &( %6/&%(, &%!+%6$)+9(,&%!+
-
8/18/2019 HBP caso clínico
16/24
-.4. Inter$""iones
F3
PRECIPITANTE
F3 OBETO MECANISMO DE INTERACCION
OMEPRAOL CLOPIDOGREL O"*!)('+& %6"%/7* &+6 *1*$+6 * &+!%+)*& (& (1*$() *& "*$(;+&%6"+ * &(6
*'%"(6
-
8/18/2019 HBP caso clínico
17/24
LEVOFLOACI
NA
GLIMEPIRIDA L*++@(%( (/"*$( &+6 *1*$+6 * &%"*!%)%( !+) 6%*)%6"+ 1()"(+%="%+.
A"%%6$)(%8 * ?/%+&+(6 + ($%;%8$%+6 !/** )*6/&$() *
-
8/18/2019 HBP caso clínico
18/24
ALBUTEROL FUROSEMIDA M*(%6"+: 6%*)%6"+ 1()"(+%="%+. I$*)(%8 "*+) + + 6%%9($%(. L(
-
8/18/2019 HBP caso clínico
19/24
'. )is"!si#n:
'I. Con"%!siones:
S* /$%&%'8 &( "*$++&+( * S*/%"%*$+ 1()"(+$*)(!3/$%+ SFT * DADER
* *& *6())+&&+ 7 )*6+&/%8 * / (6+ &%+. S* %*$%98 &+6 R*6/&$(+6 N*($%+6 * &( M*%(%8 RNM +"+ EFECTOS
* *& (6+ &%+. S* %*$%98 &+6 P)+;&*"(6 R*&(%+(+ + &+6 M*%("*$+6 PRM +"+
CA#SANTES * &+6 RNM * *& (6+ &%+.
'II. C!estion$rio:
3 E( * 5*"! ,! %(+!$1!(#%'( ,! 5*$/*#7+%#. ! +$*+*/%!(+. (.5*$/*#.+!$*&7+%#. $!#./!(,*$8*3
L+6 +;*$%+6 *& $)($("%*$+ 6+ %6"%/%) &+6 6$+"(6, "*+)() &((&%( * %( 7 *%$() &( (!()%%8 * +"!&%(%+*6. E !(%*$*6 +
6%$+"($+&+( &**-"+*)(( 7 !+( (1*$(%8 * 6/ (&%( * %( 6*
)*+"%*( /( +/$( *@!*$($* ?/* %&/7* %1+)"(%8 (& !(%*$*
6+;)* &( ($/)(&*'( ;((& * &( 6%$+"($+&+(, +6*+6 6+;)* *& *6$%&+ *
%( 7 / 6*/%"%*$+ )/$%()%+. E (&/+6 !(%*$*6 &+6 6$+"(6 !/**
"*+)() *6!+$=*("*$*, "%*$)(6 ?/* * +$)+6 6* "($%** *6$(;&*6
/)($* "/+6. #( )*%6%8 "+6$)8 ?/* ( &+ &()+ * / !*)%++ *6*/%"%*$+ * 2, ( 5 (>+6, / * &+6
-
8/18/2019 HBP caso clínico
20/24
P+) +$)+ &(+ *@%6$* *& $)($("%*$+ ?/%))%+ *6$+ 6* ( * &+6 (6+6 * &(
*@%6$*%( * 6$+"(6 )*1)($()%+6 ( $)($("%*$+ 1()"(+&8%+, (6 +"+
&( !)*6*%( * +"!&%(%+*6 %"!+)$($*6 +"+ &( )*$*%8 /)%()%(
!*)"(*$* + )*/))*$*,
-
8/18/2019 HBP caso clínico
21/24
3 P*"/! *" RAM" ! %(+!$*##%.(!" !( (* +*4* %(#)* !/!#*(%"/. ,! %(+!$*##%'(J ! %(,%! #* !" ! /!,%#*/!(+..4!+. ) &$!#%&%+*(+! ,! ." /!,%#*/!(+." !(#.(+$*,." !( !#*". #8(%#.J #./. ." #*"*(+!" PRM ,! ." RAM"J %(#)*."!( * F*"! ,! E1**#%'(3
F3
PRECIPITANTE
F3 OBETO MECANISMO DE INTERACCION
OMEPRAOL CLOPIDOGREL O"*!)('+& %6"%/7* &+6 *1*$+6 *
&+!%+)*& (& (1*$() *& "*$(;+&%6"+ * &(6
*'%"(6
-
8/18/2019 HBP caso clínico
22/24
PREDNISOLO
NA
CLOPIDOGREL P)*%6+&+( %6"%/%)= *& %*& + *& *1*$+
* &+!%+)*& (& (1*$()
-
8/18/2019 HBP caso clínico
23/24
PREDNISOLO
NA
LEVOFLOACI
NO
L( ("%%6$)(%8 +/$( * &(6 ?/%+&+(6
7 &+6 +)$%+6$*)+%*6 !/** (/"*$() *&
)%*6+ * )+$/)( *& $*8IRBESARTN ALBUTEROL D%6"%/7* *& !+$(6%+ 63)%+. E1*$+ * &(
%$*)(%8 + *6 &()(, $*( /%(+.FUROSEMIDA IRBESARTN S* )*/* *& !+$(6%+ 63)%+. E1*$+ * &(
%$*)(%8 + *6 &()(, $*( /%(+.
S%%9($%+ - %%&() * *)(ALBUTEROL FUROSEMIDA M*(%6"+: 6%*)%6"+ 1()"(+%="%+.
I$*)(%8 "*+) + + 6%%9($%(. L(
-
8/18/2019 HBP caso clínico
24/24
* %%*";)* *& 202, 20: X-. D%6!+%;&* *: